Active	Status	Sponsor type	Region	Phase	Filter
5 Active 8 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wu, Kaichun
ES101002, NCT04176588: A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis Dec 2023 - Dec 2023 : Completion of enrollment in phase 3 study of moderate-severe ulcerative colitis	Active, not recruiting	3	341	RoW	Etrasimod, Placebo	Everstar Therapeutics Limited	Moderately to Severely Active Ulcerative Colitis	07/24	10/24